GMED 📈 Globus Medical - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3795772082
GMED: Spine, Orthopedic, Trauma, Joint, Biologic, Surgical Implants
Globus Medical is a medical device company that develops and commercializes a wide range of healthcare solutions, primarily focusing on musculoskeletal disorders. Their product portfolio includes an array of spine products, such as traditional fusion implants, which encompass pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices. These solutions are designed to treat various conditions, including degenerative and congenital disorders, deformity, tumors, and trauma injuries. The company also offers motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices, providing patients with alternative treatment options.
In addition to their spine products, Globus Medical offers interventional solutions for treating vertebral compression fractures, as well as regenerative biologic products, comprising allografts and synthetic alternatives. Their product line also extends to orthopedic trauma treatment, featuring fracture plates, compression screws, intramedullary nails, and external fixation systems. Furthermore, the company provides hip and knee joint solutions, including modular hip stems, acetabular cups, and a range of knee arthroplasty implants, such as posterior stabilizing and cruciate retaining implants. This comprehensive portfolio enables Globus Medical to cater to a broad spectrum of musculoskeletal needs, making them a significant player in the healthcare industry.
Globus Medical's distribution network is multifaceted, with the company selling its products through direct sales representatives, distributors, and independent sales agents, particularly for hip and knee products. This strategic approach allows them to maintain a strong presence in the market, both domestically and internationally. With its headquarters in Audubon, Pennsylvania, and a strong online presence, Globus Medical continues to expand its reach, providing innovative healthcare solutions to patients worldwide. The company's commitment to research and development, coupled with its extensive product range, positions them as a leading medical device company, dedicated to improving patient outcomes and advancing the field of musculoskeletal healthcare.
Additional Sources for GMED Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GMED Stock Overview
Market Cap in USD | 11,657m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2012-08-03 |
GMED Stock Ratings
Growth 5y | 32.6% |
Fundamental | 15.0% |
Dividend | - |
Rel. Strength Industry | 1053 |
Analysts | 3.87/5 |
Fair Price Momentum | 83.27 USD |
Fair Price DCF | 66.82 USD |
GMED Dividends
No Dividends PaidGMED Growth Ratios
Growth Correlation 3m | 85.2% |
Growth Correlation 12m | 88.7% |
Growth Correlation 5y | 17.9% |
CAGR 5y | 6.90% |
CAGR/Mean DD 5y | 0.36 |
Sharpe Ratio 12m | 1.36 |
Alpha | 28.05 |
Beta | 1.00 |
Volatility | 30.32% |
Current Volume | 2828.7k |
Average Volume 20d | 928.3k |
As of December 21, 2024, the stock is trading at USD 82.63 with a total of 2,828,721 shares traded.
Over the past week, the price has changed by +0.25%, over one month by -1.15%, over three months by +16.97% and over the past year by +59.30%.
Neither. Based on ValueRay Fundamental Analyses, Globus Medical is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 15.01 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GMED as of December 2024 is 83.27. This means that GMED is currently overvalued and has a potential downside of 0.77%.
Globus Medical has received a consensus analysts rating of 3.87. Therefor, it is recommend to buy GMED.
- Strong Buy: 5
- Buy: 4
- Hold: 5
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, GMED Globus Medical will be worth about 92.1 in December 2025. The stock is currently trading at 82.63. This means that the stock has a potential upside of +11.51%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 90.5 | 9.6% |
Analysts Target Price | 67.3 | -18.6% |
ValueRay Target Price | 92.1 | 11.5% |